Malinauskiene Vaidota, Cijauskaite Elena, Sadauskaite Goda, Stundiene Ieva
Clinic of Gastroenterology, Nephrourology and Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 01513 Vilnius, Lithuania.
Pharmaceutics. 2025 Apr 6;17(4):476. doi: 10.3390/pharmaceutics17040476.
: This review explores the impact of gut microbiota profiles in predicting the response to anti-integrin biologic therapy, particularly vedolizumab, in inflammatory bowel disease (IBD) patients. IBD, encompassing Crohn's disease and ulcerative colitis, is a chronic inflammatory condition with a growing prevalence linked to industrialization and lifestyle changes. Disruption in the gut microbiota balance, characterized by reduced diversity and altered short-chain fatty acid (SCFA) production, is associated with IBD and its symptoms. Current pharmacological treatments target healing and remission, with vedolizumab offering a gut-selective treatment approach. : A search of the literature was performed on the relationship between anti-integrin treatment and the microbiome profile in IBD. Articles were examined from the PubMed, Medline, Cochrane, and Web of Science databases. : This review identified five human studies investigating the relationship between gut microbiome composition, SCFAs, and response to vedolizumab, revealing an increased abundance of beneficial bacteria and levels of SCFAs like butyrate in remission cases. Despite promising findings, the small sample sizes and limited scope of the existing studies highlight the need for larger, comprehensive research. : This review underscores the potential of gut microbiome and metabolite profiling as non-invasive biomarkers for IBD severity and treatment outcomes, advocating for personalized therapeutic strategies to enhance efficacy. The insights gained could lead to novel diagnostic and treatment modalities, although further validation is necessary to fully understand the intricate connections between gut microbiota and IBD prognosis.
本综述探讨了肠道微生物群谱在预测炎症性肠病（IBD）患者对抗整合素生物疗法，尤其是维多珠单抗的反应中的影响。IBD包括克罗恩病和溃疡性结肠炎，是一种慢性炎症性疾病，其患病率不断上升，与工业化和生活方式改变有关。肠道微生物群平衡的破坏，其特征是多样性降低和短链脂肪酸（SCFA）产生改变，与IBD及其症状相关。目前的药物治疗旨在实现愈合和缓解，维多珠单抗提供了一种肠道选择性治疗方法。
对IBD中抗整合素治疗与微生物组谱之间的关系进行了文献检索。从PubMed、Medline、Cochrane和科学网数据库中检索文章。
本综述确定了五项关于肠道微生物组组成、SCFAs与维多珠单抗反应之间关系的人体研究，结果显示缓解病例中有益细菌的丰度增加以及丁酸盐等SCFAs水平升高。尽管有这些有前景的发现，但现有研究的样本量小且范围有限，凸显了开展更大规模、全面研究的必要性。
本综述强调了肠道微生物组和代谢物分析作为IBD严重程度和治疗结果的非侵入性生物标志物的潜力，主张采用个性化治疗策略以提高疗效。尽管需要进一步验证以充分理解肠道微生物群与IBD预后之间的复杂联系，但所获得的见解可能会带来新的诊断和治疗方式。
